Accedi
Accedi
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrati
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Home
  2. Azioni
  3. Cina
  4. Shenzhen Stock Exchange
  5. Shenzhen Salubris Pharmaceuticals Co., Ltd.
  6. Notizie
  7. Altre lingue
    002294   CNE100000FW8

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.

(002294)
  Rapporto
Prezzo di chiusura Shenzhen Stock Exchange  -  05/12/2022
32.44 CNY   -5.37%
24/10Shenzhen Salubris Pharmaceuticals Co., Ltd. Ltd. riporta i risultati degli utili per i nove mesi conclusi il 30 settembre 2022
CI
09/08Shenzhen Salubris Pharmaceuticals Co., Ltd. Ltd. riporta i risultati degli utili per il semestre conclusosi il 30 giugno 2022
CI
08/08Salubris Pharma ottiene l'autorizzazione a condurre studi clinici su un farmaco candidato al diabete.
MT
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniFondi 
RiassuntoTutte le notizieAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
24/10Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Month..
09/08Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year ..
08/08Salubris Pharma Gets Nod to Hold Clinical Trials of Diabetes Drug Candidate
25/07Tranche Update on Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Equity Buyback Plan ann..
24/07Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Equity Buyback announced on July 25, 2021..
01/07Tranche Update on Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Equity Buyback Plan ann..
07/05Shenzhen Salubris Pharmaceuticals Co., Ltd. announced that it has received funding from..
20/04Shenzhen Salubris Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for th..
19/04Shenzhen Salubris Pharmaceuticals Co., Ltd. Approves Cash Dividend for 2021
18/04Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quar..
01/04Tranche Update on Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Equity Buyback Plan ann..
29/03Shenzhen Salubris Pharmaceuticals Co., Ltd. Proposes Dividend for 2021
29/03Shenzhen Salubris Biomedical Engineering Co., Ltd. announced that it expects to receive..
28/03Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year ..
28/01Shenzhen Salubris Pharmaceuticals Co., Ltd. announces an Increase in Equity Buyback.
04/01Tranche Update on Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Equity Buyback Plan ann..
2021Salubris Biotherapeutics Inc. announced that it has received $32 million in funding fro..
2021Pinduoduo Names New Finance Vice President; Shares Jump
2021Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Month..
2021Tranche Update on Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Equity Buyback Plan ann..
2021Shenzhen Salubris Pharmaceuticals Co., Ltd. announces an Increase in Equity Buyback.
2021Viracta Up 5% After It Reacquires Rights to Combination Therapy in China
2021Viracta Therapeutics : Reacquires Exclusive Rights to Combination T..
2021Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year ..
2021Skillful Craftsman Education Technology : Names Daw..
2021Shenzhen Salubris Pharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 200 mil..
2021Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE :..
2021Shenzhen Salubris Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.
2021Salubris Biotechnology Co., Ltd. announced that it expects to receive CNY 263.8 million..
2021Shenzhen Salubris Pharmaceuticals Co., Ltd. announced that it has received CNY 1.951871..
2021ROSY METRO LIMITED acquired a 13.78% stake in M.A. Med Alliance S.A from Shenzhen Salub..
2021Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quar..
2021NORTAI International Ltd. announced that it expects to receive $80 million in funding f..
2021Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year ..
2020Shenzhen Salubris Biomedical Engineering Co., Ltd. announced that it has received CNY 3..
2020Tranche Update on Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Equity Buyback Plan ann..
2020Shenzhen Salubris Biomedical Engineering Co., Ltd. announced that it expects to receive..
2020Shenzhen Salubris Pharma Plans to Spin Off Unit for Listing
2020Shenzhen Salubris Pharmaceuticals Co., Ltd. agreed to spin-off its biomedical engineeri..
2020Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Month..
2020Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Equity Buyback announced on October 8, 20..
2020Shenzhen Salubris Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 2 ..
2020CLSA Asset Management Limited signed the share transfer agreement to acquire 5% stake i..
2020CAP V Mauritius Limited managed by The Carlyle Grou..
2020Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year ..
2020Tranche Update on Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Equity Buyback Plan ann..
2020Shenzhen Salubris Pharmaceuticals Co., Ltd. Announces to Implement Final Cash Distribut..
2020Shenzhen Salubris Pharmaceuticals Co., Ltd. Approves Final Cash Dividend for the Year 2..
2020Shenzhen Salubris Pharmaceuticals Co., Ltd. completed the acquisition of remaining 15.7..
2020Shenzhen Salubris Pharmaceuticals Co., Ltd. Announces Final Cash Dividend
2020Shenzhen Salubris Pharmaceuticals Co., Ltd. intends to sign an equity transfer agreemen..
2020Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year ..
2020Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quar..
2020Tranche Update on Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Equity Buyback Plan ann..
2020Shenzhen Salubris Pharmaceuticals Co., Ltd. Announces Management Changes
2020Tranche Update on Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Equity Buyback Plan ann..
2019Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Month..
2019Shenzhen Salubris Pharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 500 mil..
2019Shenzhen Salubris Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.
2019NORTAI International Ltd. announced that it expects to receive CNY 51.741026 million in..
2019Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year ..
2019Shenzhen Salubris Pharmaceuticals Co., Ltd.(XSEC:00..
2019Mercator MedSystems, Inc. announced that it has received $14.333502 million in funding ..
2019Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quar..
2019Shenzhen Salubris Pharmaceuticals Co., Ltd. Announces Final Distribution Plan for the Y..
2019Shenzhen Salubris Pharmaceuticals Co., Ltd. Approves Final Cash Dividend for the Year 2..
2019Shenzhen Salubris Pharmaceuticals Co., Ltd. Proposes 2018 Full Year Dividend
2019Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year ..
2018Viracta and Salubris Announce Partnership to Bring Novel Treatment for Viral-Associated..
2018NORTAI International Ltd. announced that it expects to receive HKD 78.6517 million in f..
2018Shenzhen Salubris Pharmaceuticals Co., Ltd. agreed to acquire remaining 2% stake in hen..
2018Shenzhen Salubris Pharmaceuticals Co., Ltd. completed the acquisition of remaining 10% ..
2018Genekey Biotech Co., Ltd. announced that it has received CNY 380 million in funding fro..
2018Shenzhen Salubris Pharmaceuticals Co., Ltd. intends to acquire Suzhou Huan Chen Medical..
2018Shenzhen Salubris Pharmaceuticals: Announces Investment and In-Licensing Agreement With M..
2018M.A. Med Alliance SA announced that it expects to receive $20 million in funding from S..
2018Salubris Biotherapeutics Inc. announced that it expects to receive CNY 63.9 million in ..
2018Shenzhen Salubris Pharmaceuticals Co., Ltd. agreed to acquire remaining 10% stake in Ge..
2018Genekey Biotech Co., Ltd. announced that it expects to receive CNY 380 million in fundi..
2018Mercator MedSystems, Inc. announced that it expects to receive $14.999997 million in fu..
2018Salubris Announces Final Distribution Plan to Be Implemented (A Shares) for the Year 20..
2018Salubris Approves Final Cash Dividend for the Year 2017
2018NORTAI International Ltd. announced that it expects to receive CNY 150 million in fundi..
2018Kingstronbio Co., Ltd. announced that it has received CNY 125 million in funding from S..
2018Salubris Proposes Final Cash Dividend for the Year 2017
2018Kingstronbio Co., Ltd. announced that it expects to receive CNY 125 million in funding ..
2018Shenzhen Salubris Pharmaceuticals Co., Ltd. signed a share transfer agreement to acquir..
2017Suzhou Genemen Biotech Co., Ltd. announced that it expects to receive CNY 550 million i..
2017An unknown seller sold 1.2% stake in Shenzhen Salubris Pharmaceuticals Co., Ltd..
2017Shenzhen Salubris Pharmaceuticals Co., Ltd. Approves Dividend for the Year 2016
2017Shenzhen Salubris Pharmaceuticals Co., Ltd. Proposes Cash Dividend for 2016
2016Shenzhen Salubris Pharmaceuticals Co., Ltd. cancelled the agreement to acquire 60% stak..
2016Shenzhen Salubris Pharmaceuticals Co., Ltd., its management personnel and project manag..
2016Salubris Pharmaceuticals' Unit To Acquire Salubris Biotherapeutics
2016Yalun Biotechnology Co., Ltd. announced that it expects to receive CNY 30 million in fu..
2016Shenzhen Salushenzhen Salubris Pharmaceuticals Co., Ltd. Announces Final Cash Dividend ..
2016Shenzhen Salubris Pharmaceuticals Co., Ltd Proposes Cash Dividend for 2015
2015Chengdu Jinkai Biology Engineering Co., Ltd. announced that it expects to receive CNY 3..
2015Shenzhen Salubris Pharmaceuticals Co., Ltd. agreed to acquire 60% stake in Shenzhen KYD..
2015Suzhou Genemen Biotech Co., Ltd. announced that it has received CNY 150 million in fund..
Prossimo evento su SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.